Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

Genomic classification and prognosis in acute myeloid leukemia

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · see citing works

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · see citing works

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776 · see citing works

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465 · cited 1× · see citing works

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396 · see citing works

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D. G. F., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L. R., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 347 · see citing works

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

Walter, M. J., Shen, D., Shao, J., Ding, L., White, B. S., Kandoth, C., Miller, C. A., Niu, B., McLellan, M. D., Dees, N. D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.58 · Cited by 284 · cited 1× · see citing works

Eprenetapopt Plus Azacitidine in <i>TP53</i> -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02342 · Cited by 279 · see citing works

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G. M., Jabbour, E. J., Konopleva, M. Y., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261 · see citing works

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261 · see citing works

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

Stengel, A., Kern, W., Haferlach, T., Meggendorfer, M., Fasan, A., & Haferlach, C. (2016) · Leukemia · doi:10.1038/leu.2016.263 · Cited by 244 · see citing works

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231 · see citing works

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

Oran, B., Lima, M. J. G. D., Garcia‐Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C. M., Giralt, S. A., Rondón, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 222 · see citing works

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Short, N. J., Bravo, G. M., Hwang, H., Ning, J., Franquiz, M. J., Kanagal‐Shamanna, R., Patel, K. P., Dinardo, C. D., Ravandi, F., Garcia‐Manero, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003120 · Cited by 181 · see citing works

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death &amp; Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · see citing works

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Pusic, I., Choi, J., Fiala, M. A., Gao, F., Holt, M. S., Cashen, A. F., Vij, R., Abboud, C. N., Stockerl-Goldstein, K. E., Jacoby, M. A., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.026 · Cited by 164 · see citing works

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

Maziarz, R. T., Levis, M. J., Patnaik, M. M., Scott, B. L., Mohan, S. R., Deol, A., Rowley, S. D., Kim, D. D. H., Hernandez, D., Rajkhowa, T., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01153-1 · Cited by 155 · see citing works

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy

Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137 · see citing works

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133 · see citing works

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia

Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132 · see citing works

Impact of the variant allele frequency of <i>ASXL1</i> , <i>DNMT3A</i> , <i>JAK2</i> , <i>TET2</i> , <i>TP53</i> , and <i>NPM1</i> on the outcomes of patients with newly diagnosed acute myeloid leukemia

Sasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer · doi:10.1002/cncr.32566 · Cited by 101 · see citing works

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., Chevallier, P., Vigouroux, S., Péterlin, P., Garnier, A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0536-y · Cited by 99 · see citing works

Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)

Degtjarik, O., Golovenko, D., Diskin-Posner, Y., Abrahmsén, L., Rozenberg, H., & Shakked, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-27142-6 · Cited by 78 · see citing works

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution

Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., Feng, J., Wang, P. P.-S., Babic, M., Parker, W. T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0479-8 · Cited by 62 · see citing works

Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia

Kim, H., Kim, Y., Kang, D., Kim, H. S., Lee, J.-M., Kim, M., & Cho, B. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00500-9 · Cited by 61 · see citing works

Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation

Britt, A., Mohyuddin, G. R., McClune, B., Singh, A., Lin, T., Ganguly, S., Abhyankar, S., Shune, L., McGuirk, J., Skikne, B., et al. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106402 · Cited by 21 · see citing works

Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study

Byrne, M. T., Kurian, T., Patel, D. A., et al. (2021) · Blood · doi:10.1182/blood-2021-154151 · Cited by 17 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115 · see citing works

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

Versluis, J., Saber, W., Tsai, H. K., Gibson, C. J., Dillon, L. W., Mishra, A., McGuirk, J., Maziarz, R. T., Westervelt, P., Hegde, P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00866 · Cited by 78 · see citing works

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 20 · see citing works

Azacitidine improves survival in myelodysplastic syndromes

Rose, M. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.125 · Cited by 5 · see citing works

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide

Loiseau, C., Ali, A., & Itzykson, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.014 · Cited by 9 · see citing works

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Navada, S. C., Garcia‐Manero, G., Hearn, K. P., et al. (2017) · Leukemia Research · doi:10.1016/s0145-2126(17)30156-x

Safety and efficacy of azacitidine in myelodysplastic syndromes

Vigil, C. E., García-Manero, G., & Martin-Santos (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s3143 · Cited by 38 · see citing works

Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion

Fenaux, P., Bowen, D., Gattermann, N., Hellström‐Lindberg, E., Hofmann, W., Pfeilstöcker, M., Sanz, G. F., & Santini, V. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.05.021 · Cited by 48 · see citing works